Galsulfase: profile and news
International Approvals: Tamiflu, Macugen, Naglazyme Feb 13, 2006
...aged 1 through 12 years; pegaptanib sodium injection for the treatment of neovascular (wet) age-related macular degeneration; and galsulfase injection for long ... - Medscape (subscription)
BioMarin to Present at Cowen & Co. 26th Annual Health Care ... Feb 27, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - Yahoo! News (press release)
BioMarin Announces Fourth Quarter and Year-End 2005 Financial ... Feb 23, 2006
...spending, leading to a significant reduction in our projected 2006 net loss as compared to 2005." Net sales of Naglazyme(TM) (galsulfase), an enzyme ... - PR Newswire (press release),
BioMarin Announces Fourth Quarter and Year-End 2005 Financial ... Feb 23, 2006
Net sales of Naglazyme(TM) (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), for the fourth quarter and year ended December 31 ... - PR Newswire (press release),
BioMarin Receives Marketing Approval for Naglazyme in European ... Jan 30, 2006
...(Nasdaq and SWX: BMRN) announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific ... - MSN Money
BioMarin Receives Marketing Approval for Naglazyme in European ... Jan 30, 2006
...announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment approved in the ... - PharmaLive.com (press release),
BioMarin Establishes Commercial Operations in Europe Jan 10, 2006
...that it has established commercial operations in Europe in anticipation of receiving European marketing approval for Naglazyme(TM) (galsulfase), an enzyme ... - PR Newswire (press release),
BioMarin Receives FDA Fast Track Designation for Phenoptin for PKU Jan 25, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PR Newswire (press release),
BioMarin Receives Marketing Approval for Naglazyme in European ... Jan 31, 2006
...announced yesterday that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment approved in ... - DG News
BioMarin to Host Research and Development Day on Tuesday, December ... Nov 22, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PR Newswire (press release),
Committee for Medicinal Products for Human Use Summary of Opinion ... Sep 16, 2005
...therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; Nacetylgalactosamine 4-sulphatase (galsulfase) deficiency; Maroteaux-Lamy ... - PharmaLive.com (press release),
BioMarin Announces Positive Opinion for Naglazyme From European ... Sep 15, 2005
Evaluation Agency (EMEA), has issued a positive opinion on the company's Marketing Authorization Application for Naglazyme(TM) (galsulfase) an investigational ... - PR Newswire (press release),
BioMarin to Present at the 2005 UBS Global Life Science Conference Sep 20, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PharmaLive.com (press release),
BioMarin to Present at the NewsMakers in the Biotech Industry ... Sep 7, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PR Newswire (press release),
FDA Approvals: Naglazyme, Trizivir, Levaquin Aug 11, 2005
11, 2005 — The US Food and Drug Administration (FDA) has approved galsulfase 1-mg/mL injection to improve endurance in patients with mucopolysaccharidosis VI ... - Medscape (subscription)
